34results about How to "Maintain effective plasma concentration" patented technology

The invention discloses a fentanyl double-layer buccal tablet and a preparation method thereof. The buccal tablet is composed by a quick release layer (an outer layer) and a sustained release layer (an inner layer) which form a biphasic drug release system. The quick release layer is prepared by effervescence and cyclodextrin inclusion technologies, a transient change of a pH value happens around the tablet by utilizing an effervescence reaction, and the quick release layer rapidly disintegrates and releases fentanyl in a few minutes; the sustained release layer slowly releases drugs to maintain an effective plasma concentration for up to a few hours. The buccal tablet releases the drugs from fast to slow, maintains the effective plasma concentration for a long time, is easy to use, is safe and reliable, and has the characteristics of rapid and continuous analgesia.

The invention provides a diclofenac potassium sustained-release capsule which is anti-inflammation and analgesic drug, and a production method thereof. The diclofenac potassium sustained-release capsule is formed by preparing diclofenac potassium into sustained-release pellets and then filling the pellets into the capsule; the diclofenac potassium sustained-release pellet consists of a blank pellet core taken as mother nucleus, a main drug layer which is coated outside of the pellet core and contains diclofenac potassium and a sustained-release coating layer covered on the main drug layer. The diclofenac potassium sustained-release capsule of the invention has fine preparation stability and prominent release effect.

The invention discloses a felodipine sustained-release tablet and a preparation technology thereof. According to the preparation technology of the felodipine sustained-release tablet, fast-release solid dispersions, sustained-release micro-pills and pharmaceutically acceptable accessories are mixed and the mixture is compressed to obtain the preparation. The fast-release solid dispersions comprise felodipine, copovidone and polacrilin potassium; the sustained-release micro pills are obtained by coating the fast-release solid dispersions with the ethyl cellulose film with a pore-forming agent. The sustained-release tablet disclosed by the invention has the advantages of fast early-stage releasing speed and slow and stable later-stage releasing speed, so that the drug can be completely released and an effective blood drug concentration can be maintained for a long time; the felodipine sustained-release tablet is high in bioavailability, simple in preparation technology and applicable to industrial mass production.

The invention relates to a slow-release tablet comprising succinate frovatriptan. The slow-release tablet comprises a tablet core and a coating, wherein the tablet core adopts a matrix tablet, and comprises succinate frovatriptan, hydroxypropyl methylcellulose, pregelatinized starch, magnesium stearate, talcum powder, and a 95% ethanol solution; the coating comprises a slow-release coating material, polyethylene glycol and succinate frovatriptan. The slow-release tablet has the advantages that the administration number of times is reduced, the compliance of a patient is improved, and the effective blood concentration is kept for a relatively long time.

The invention relates to a levofloxacin hydrochloride micropill capsule and a preparation method thereof. The levofloxacin hydrochloride micropill capsule comprises a pill core, a medicament-containing layer, a sustained-release coating layer and a quick-release layer, wherein levofloxacin hydrochloride is contained in the medicament-containing layer and the quick-release layer; and the sustained-release coating layer comprises the following materials in percentage by weight: 20 to 60 percent of levofloxacin hydrochloride, 30 to 55 percent of pill core, 10 to 25 percent of binding agent, 3 to 5 percent of sustained-release coating material, 0.3 to 3 percent of pore-forming agent and 0.1 to 1 percent of plasticizer. The levofloxacin hydrochloride micropill capsule has the advantages of high stability, small local stimulation of medicaments, high bioavailability and the like. Due to the adoption of a fluidized bed, the problems of large dust and low yield in a method of powder agglomerating in the background technology are solved.

The invention relates to the technical field of medicines and provides a metformin hydrochloride medicine composition as well as a preparation method and application thereof. The metformin hydrochloride medicine composition comprises the following components in parts by weight: 100-150 parts of metformin hydrochloride, 5-10 parts of pregelatinized starch, 5-10 parts of mannitol and 1-5 parts of magnesium stearate. The preparation method comprises the following steps: uniformly mixing the metformin hydrochloride, the pregelatinized starch and the mannitol, adding water to pelletize, further adding the magnesium stearate, and uniformly mixing, thereby obtaining capsules or tablets. According to the embodiment of the invention, contents of the metformin hydrochloride, the pregelatinized starch and the mannitol are limited, medicines are slowly released in bodies, direct irritation of the metformin hydrochloride to gastrointestinal tracts can be alleviated, side effects, particularly serious gastrointestinal tract reactions, can be reduced, an effective blood concentration can be maintained, the compliance and the security of medicine taking can be improved for patients, the patients can tolerate the composition, and long-term treatment can be facilitated.

The invention relates to the technical field of medicine, and provides a moxifloxacin hydrochloride pharmaceutical composition, a preparation method and application thereof. The moxifloxacin hydrochloride pharmaceutical composition comprises, in parts by weight, 40-50 parts of moxifloxacin hydrochloride, 4-5 parts of pregelatinized starch, 10-15 parts of microcrystalline cellulose, cross-linked carboxymethyl 3-4 parts of cellulose sodium and 0.3-1 part of magnesium stearate; the preparation method comprises mixing moxifloxacin hydrochloride, pregelatinized starch, microcrystalline cellulose and cross-linked carboxymethyl cellulose sodium, adding water Granulate, then add magnesium stearate, mix well and make capsules or tablets. In this example, by limiting the content of the components, the drug can be released slowly in the body, reducing the direct stimulation of moxifloxacin hydrochloride to the gastrointestinal tract, thereby reducing its side effects, especially the occurrence of severe gastrointestinal reactions, and improving the quality of the patients. The compliance and safety of medication make it easier for patients to tolerate and benefit long-term treatment.

The present invention relates to a docetaxel nanometer lipid injection. The invention also relates to a method for preparing the docetaxel nanometer lipid injection. The invention further relates to the application of the docetaxel nanometer lipid injection for preparing medicament for treating a tumor. The nanometer preparation of the invention is capable of prolonging the medicament action time,conveying the medicament with a target, reducing the administration dose under the precondition of ensuring the medicament action, alleviating or avoiding medicament toxin and side effects, improvingthe medicament action stability, and being benefited for the medicament storage, thus it is capable of implementing the development of the medicament which has advantages in the aspects of a high yield, automatization, large scale, low cost, convenient carry and storage, small dose and low side-effect.